Resverlogix Corp. announced an overnight marketed offering of its common shares and common share purchase warrants.
The Canadian clinical stage biotechnology company has 105,701,543 common shares issued and outstanding.
The offering is led by Bloom Burton Securities Inc. on a best-efforts agency basis.
It is being made in every Canadian province, except Quebec, by way of a prospectus supplement to Resverlogix's base shelf prospectus dated Oct. 1, 2015.
The number and price of units to be distributed, and the exercise price and term of each whole common share purchase warrant will be determined in context of the market.